Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response

Journal of Thrombosis and Haemostasis

Volumn 16, Issue 6, 2018, Pages 1198-1210

  Pasalic, L ^a,b,c   Wing Lun, E ^d   Lau, J K ^e,f   Campbell, H ^a   Pennings, G J ^e   Lau, E ^b,c   Connor, D ^g   Liang, H P ^e   Muller, D ^d   Kritharides, L ^e,f   Hogg, P J ^e,h   Chen, V M ^a,e,f  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c Sydney Centres for Thrombosis and Haemostasis   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f ANZAC Research Institute   (Australia)

^g Blood   (Australia)

^h CENTENARY INSTITUTE   (Australia)

Author keywords

coronary artery disease; flow cytometry; platelet activation; platelet aggregation inhibitors; platelet function studies; procoagulant platelets

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CELL MARKER; CLOPIDOGREL; COLLAGEN; PADGEM PROTEIN; PRASUGREL; THROMBIN; TICAGRELOR; UNCLASSIFIED DRUG; [4 [N [[S GLUTATHIONYL]ACETYL]AMINO]PHENYLARSONOUS ACID]; 4-(N-(S-GLUTATHIONYLACETYL)AMINO)PHENYLARSENOXIDE; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; GLUTATHIONE; ORGANOARSENIC DERIVATIVE; SELP PROTEIN, HUMAN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG TARGETING; DUAL ANTIPLATELET THERAPY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROCOAGULANT PLATELET; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; CASE CONTROL STUDY; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES;

AGED; ARSENICALS; ASPIRIN; BIOMARKERS; BLOOD COAGULATION; BLOOD PLATELETS; CASE-CONTROL STUDIES; CLOPIDOGREL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; GLUTATHIONE; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS;

EID: 85047810362     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.14008     Document Type: Article

References (43)

1. Heemskerk JWM, Mattheij NJA, Cosemans JMEM. Platelet-based coagulation: different populations, different functions. J Thromb Haemost 2013; 11: 2–16.
2. McFadyen JD, Jackson SP. Differentiating haemostasis from thrombosis for therapeutic benefit. Thromb Haemost 2013; 110: 859–67.
3. Bouchard BA, Silveira JR, Tracy PB. Chapter 21 - interactions between platelets and the coagulation system. In: Michelson AD, ed. Platelets (3rd Edn). Cambridge: Academic Press, 2013: 425–51.
4. Munnix ICA, Kuijpers MJE, Auger J, Thomassen CMLGD, Panizzi P, van Zandvoort MAM, Rosing J, Bock PE, Watson SP, Heemskerk JWM. Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation. Arterioscler Thromb Vasc Biol 2007; 27: 2484–90.
5. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005; 111: 3481–8.
6. Freynhofer MK, Bruno V, Wojta J, Huber K. The role of platelets in athero-thrombotic events. Curr Pharm Des 2012; 18: 5197–214.
7. Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev 2013; 93: 327–58.
8. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381–9.
9. Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 2006; 26: 41–8.
10. Monaco C, Mathur A, Martin JF. What causes acute coronary syndromes? Applying Koch's postulates. Atherosclerosis 2005; 179: 1–15.
11. Hua VM, Chen VMY. Procoagulant platelets and the pathways leading to cell death. Semin Thromb Hemost 2015; 41: 405–12.
12. Fager AM, Wood JP, Bouchard BA, Feng P, Tracy PB. Properties of procoagulant platelets: defining and characterizing the subpopulation binding a functional prothrombinase. Arterioscler Thromb Vasc Biol 2010; 30: 2400–7.
13. Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of α-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood 2000; 95: 1694–702.
14. Kempton CL, Hoffman M, Roberts HR, Monroe DM. Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations. Arterioscler Thromb Vasc Biol 2005; 25: 861–6.
15. London FS, Marcinkiewicz M, Walsh PN. A subpopulation of platelets responds to thrombin- or SFLLRN-stimulation with binding sites for factor IXa. J Biol Chem 2004; 279: 19854–9.
16. Hua VM, Abeynaike L, Glaros E, Campbell H, Pasalic L, Hogg PJ, Chen VM. Necrotic platelets provide a procoagulant surface during thrombosis. Blood 2015; 126: 2852–62.
17. Park D, Don AS, Massamiri T, Karwa A, Warner B, MacDonald J, Hemenway C, Naik A, Kuan KT, Dilda PJ, Wong JW, Camphausen K, Chinen L, Dyszlewski M, Hogg PJ. Noninvasive imaging of cell death using an Hsp90 ligand. J Am Chem Soc 2011; 133: 2832–5.
18. Don AS, Kisker O, Dilda P, Donoghue N, Zhao X, Decollogne S, Creighton B, Flynn E, Folkman J, Hogg PJ. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 2003; 3: 497–509.
19. Park D, Xie BW, Van Beek ER, Blankevoort V, Que I, Lowik CW, Hogg PJ. Optical imaging of treatment-related tumor cell death using a heat shock protein-90 alkylator. Mol Pharm 2013; 10: 3882–91.
20. Pasalic L, Pennings GJ, Connor D, Campbell H, Kritharides L, Chen VM. Flow cytometry protocols for assessment of platelet function in whole blood. Methods Mol Biol 2017; 1646: 369–89.
21. Yong AS, Pennings GJ, Chang M, Hamzah A, Chung T, Qi M, Brieger D, Behnia M, Krilis SA, Ng MK, Lowe HC, Kritharides L. Intracoronary shear-related up-regulation of platelet P-selectin and platelet-monocyte aggregation despite the use of aspirin and clopidogrel. Blood 2011; 117: 11–20.
22. Pennings GJ, Yong AS, Kritharides L. Expression of EMMPRIN (CD147) on circulating platelets in vivo. J Thromb Haemost 2010; 8: 472–81.
23. Shi J, Heegaard CW, Rasmussen JT, Gilbert GE. Lactadherin binds selectively to membranes containing phosphatidyl-L-serine and increased curvature. Biochim Biophys Acta 2004; 1667: 82–90.
24. Butenas S, van't Veer C, Mann KG. “Normal” thrombin generation. Blood 1999; 94: 2169–78.
25. Berny MA, Munnix IC, Auger JM, Schols SE, Cosemans JM, Panizzi P, Bock PE, Watson SP, McCarty OJ, Heemskerk JW. Spatial distribution of factor Xa, thrombin, and fibrin(ogen) on thrombi at venous shear. PLoS ONE 2010; 5: e10415.
26. Pasalic L, Wang SS, Chen VM. Platelets as biomarkers of coronary artery disease. Semin Thromb Hemost 2016; 42: 223–33.
27. Silvain J, Collet J-P, Nagaswami C, Beygui F, Edmondson KE, Bellemain-Appaix A, Cayla G, Pena A, Brugier D, Barthelemy O, Montalescot G, Weisel JW. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol 2011; 57: 1359–67.
28. Sadowski M, Zabczyk M, Undas A. Coronary thrombus composition: links with inflammation, platelet and endothelial markers. Atherosclerosis 2014; 237: 555–61.
29. Kaplan ZS, Jackson SP. The role of platelets in atherothrombosis. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program 2011; 2011: 51–61.
30. Mohammed BM, Contaifer D Jr, Lastrapes KK, Martin EJ, Mazepa MA, Hoffman M, Monroe DM, Brophy DF. Coated platelet assay: a feasible approach to a complicated science. Haemophilia 2016; 22: e67–70.
31. Remenyi G, Szasz R, Friese P, Dale GL. Role of mitochondrial permeability transition pore in coated-platelet formation. Arterioscler Thromb Vasc Biol 2005; 25: 467–71.
32. Frelinger AL 3rd, Jakubowski JA, Li Y, Barnard MR, Linden MD, Tarnow I, Fox ML, Sugidachi A, Winters KJ, Furman MI, Michelson AD. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost 2008; 6: 359–65.
33. Bevers EM, Williamson PL. Getting to the outer leaflet: physiology of phosphatidylserine exposure at the plasma membrane. Physiol Rev 2016; 96: 605–45.
34. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
35. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–60.
36. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373–83.
37. Lecut C, Schoolmeester A, Kuijpers MJ, Broers JL, van Zandvoort MA, Vanhoorelbeke K, Deckmyn H, Jandrot-Perrus M, Heemskerk JW. Principal role of glycoprotein VI in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation. Arterioscler Thromb Vasc Biol 2004; 24: 1727–33.
38. Vanschoonbeek K, Feijge MAH, Van Kampen RJW, Kenis H, Hemker HC, Giesen PLA, Heemskerk JWM. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost 2004; 2: 476–84.
39. Norgard NB, Saya S, Hann CL, Hennebry TA, Schechter E, Dale GL. Clopidogrel attenuates coated-platelet production in patients undergoing elective coronary catheterization. J Cardiovasc Pharmacol 2008; 52: 536–9.
40. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502.
41. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791–800.
42. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155–66.
43. ADPtest Package Insert (06673686001V2). Roche Diagnostics Gmbh, 2012.